ABRx™ Antibiotic Resistance Panel Detects 17 Resistance Genes
Diatherix Laboratories, LLC has launched the ABRx™ Antibiotic Resistance Panel, a diagnostic test for detection of 17 antibiotic resistance genes. Used on properly collected specimens taken directly from the infectious process, the ABRx™ Panel can enhance result times and diagnostic accuracy, providing physicians and pharmacists with clinically important information to benefit both patient outcomes and hospital quality measures.
The ABRx™ Panel detects clinically problematic and prevalent antibiotic resistance genes that lead to resistance to some of the most commonly prescribed antibiotics: penicillins, cephalosporins, monobactams, carbapenems, macrolides and fluoroquinolones. The molecular identification of antibiotic resistance is an innovative approach in clinical diagnostics when compared to antibiotic susceptibility testing performed in routine laboratories.
More information about the ABRx™ Panel can be found in this technical bulletin.
Tags: Antibiotic Resistance
Date Published: October 11, 2016
Source article link: DIATHERIX Laboratories, Inc » company contact details
New Software Improves Antibiotic SIR Determination Using Latest EUCAST Rules
FDA-Cleared Liofilchem MTS™ (MIC Test Strip) Ceftazidime-avibactam (CZA)
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Linezolid (LNZ)
Ultrafast PCR (10 Mins or Less) Showcased at Analytica 2018
CE-IVD Marked Unyvero UTI Cartridge Covers 103 Diagnostic Targets